Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 1316390, 6 pages
https://doi.org/10.1155/2018/1316390
Research Article

Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies

1Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego St. 49, 60-355 Poznań, Poland
2Department of Cell Biology, Poznan University of Medical Sciences, Rokietnicka St. 5D, 60-806 Poznań, Poland
3Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka St. 5A, 60-806 Poznań, Poland
4Department of General Surgery and Multiple Trauma and Division of Gastroenterological and Endocrine Surgery, Provincial Hospital, Juraszów St. 7/19, 60-479 Poznań, Poland

Correspondence should be addressed to Nadia Sawicka-Gutaj; lp.2o@ahyn

Received 13 October 2017; Revised 24 December 2017; Accepted 8 January 2018; Published 6 February 2018

Academic Editor: Fabrizio Montecucco

Copyright © 2018 Nadia Sawicka-Gutaj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. B. Dahl, S. Holm, P. Aukrust, and B. Halvorsen, “Visfatin/NAMPT: A multifaceted molecule with diverse roles in physiology and pathophysiology,” Annual Review of Nutrition, vol. 32, pp. 229–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Lago, C. Dieguez, J. Gómez-Reino, and O. Gualillo, “The emerging role of adipokines as mediators of inflammation and immune responses,” Cytokine & Growth Factor Reviews, vol. 18, no. 3-4, pp. 313–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Stofkova, “Resistin and visfatin: Regulators of insulin sensitivity, inflammation and immunity,” Endocrine Regulations, vol. 44, no. 1, pp. 25–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Hunter, Adipokines, Science Publishers, 2011. View at Publisher · View at Google Scholar
  5. I. Kowalska, “Role of adipose tissue in the development of vascular complications in type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 78, no. 3, pp. S14–S22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Sawicka-Gutaj, J. Waligórska-Stachura, M. Andrusiewicz et al., “Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression,” Tumor Biology, vol. 36, no. 10, pp. 7859–7863, 2015. View at Publisher · View at Google Scholar
  7. R. Shackelford, S. Hirsh, K. Henry, A. Abdel-Mageed, E. Kandil, and D. Coppola, “Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas,” Anticancer Reseach, vol. 33, no. 8, pp. 3047–3052, 2013. View at Google Scholar · View at Scopus
  8. D. Sampath, T. S. Zabka, D. L. Misner, T. O'Brien, and P. S. Dragovich, “Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer,” Pharmacology & Therapeutics, vol. 151, pp. 16–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Travelli, S. Morlacchi, U. Galli, G. C. Tron, A. A. Genazzani, and A. Sica, “Abstract 393: Nicotinamide phosphoribosyl transferase (NAMPT) inhibitors: novel modulators of antitumor immunity,” Cancer Research, vol. 75, no. 15 Supplement, pp. 393–393, 2015. View at Publisher · View at Google Scholar
  10. N. Sawicka-Gutaj, B. Budny, A. Zybek-Kocik et al., “Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves’ opthalmopathy,” Endocrine Journal, vol. 53, no. 2, pp. 497–504, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Sawicka-Gutaj, A. Zybek-Kocik, A. Klimowicz et al., “Circulating visfatin in hypothyroidism is associated with free thyroid hormones and antithyroperoxidase antibodies,” International Journal of Endocrinology, vol. 2016, Article ID 7402469, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ruchała and N. Sawicka-Gutaj, “Advances in the pharmacological treatment of Graves’ orbitopathy,” Expert Review of Clinical Pharmacology, vol. 9, no. 7, pp. 981–989, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Sawicka-Gutaj, T. Bednarczuk, J. Daroszewski et al., “GO-QOL - Disease-specific quality of life questionnaire in Graves' orbitopathy,” Endokrynologia Polska, vol. 66, no. 4, pp. 362–366, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Hiromatsu, D. Yang, T. Bednarczuk, I. Miyake, K. Nonaka, and Y. Inoue, “Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 3, pp. 1194–1199, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Otero, R. Logo, R. Gomez et al., “Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1198–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Brentano, O. Schorr, C. Ospelt et al., “Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities,” Arthritis & Rheumatism, vol. 56, no. 9, pp. 2829–2839, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. H. Rho, J. Solus, T. Sokka et al., “Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 60, no. 7, pp. 1906–1914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Sglunda, H. Mann, H. Hulejová et al., “Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: Data from the PERAC cohort,” PLoS ONE, vol. 9, no. 7, Article ID e103495, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Del Prete, V. Salvi, and S. Sozzani, “Adipokines as potential biomarkers in rheumatoid arthritis,” Mediators of Inflammation, vol. 2014, Article ID 425068, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. R. Moschen, A. Kaser, B. Enrich et al., “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties,” The Journal of Immunology, vol. 178, no. 3, pp. 1748–1758, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Ismail and S. A. Mohamed, “Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity,” British Journal of Dermatology, vol. 167, no. 2, pp. 436–439, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Luk, Z. Malam, and J. C. Marshall, “Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity,” Journal of Leukocyte Biology, vol. 83, no. 4, pp. 804–816, 2008. View at Publisher · View at Google Scholar
  23. M. Nowak, L. Siemińska, J. Karpe, B. Marek, B. Kos-Kudła, and D. Kajdaniuk, “Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy,” Journal of Endocrinological Investigation, vol. 39, no. 1, pp. 63–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Shen, Z. Li, W. Li et al., “Th1, Th2, and Th17 cytokine involvement in thyroid associated ophthalmopathy,” Disease Markers, vol. 2015, Article ID 609593, 6 pages, 2015. View at Publisher · View at Google Scholar
  25. K. Krohn, D. Führer, Y. Bayer et al., “Molecular pathogenesis of euthyroid and toxic multinodular goiter,” Endocrine Reviews, vol. 26, no. 4, pp. 504–524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. L. Franks and J. E. Slansky, “Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer,” Anticancer Reseach, vol. 32, no. 4, pp. 1119–1136, 2012. View at Google Scholar · View at Scopus
  27. L. H. Duntas and B. Biondi, “The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin,” Thyroid, vol. 23, no. 6, pp. 646–653, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Lu, L. T. Hiraki, J. A. Sparks et al., “Being overweight or obese and risk of developing rheumatoid arthritis among women: A prospective cohort study,” Annals of the Rheumatic Diseases, vol. 73, no. 11, pp. 1914–1922, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Versini, P.-Y. Jeandel, E. Rosenthal, and Y. Shoenfeld, “Obesity in autoimmune diseases: not a passive bystander,” Autoimmunity Reviews, vol. 13, no. 9, pp. 981–1000, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Hutcheson, “Adipokines influence the inflammatory balance in autoimmunity,” Cytokine, vol. 75, no. 2, pp. 272–279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Oeser, C. P. Chung, Y. Asanuma, I. Avalos, and C. M. Stein, “Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 52, no. 11, pp. 3651–3659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Bilski, A. I. Mazur-Bialy, M. Wierdak, and T. Brzozowski, “The impact of physical activity and nutrition on inflammatory bowel disease: The potential role of cross talk between adipose tissue and skeletal muscle.,” Journal of Physiology and Pharmacology, vol. 64, no. 2, 2013. View at Google Scholar · View at Scopus
  33. P. Fleming, J. Kraft, W. P. Gulliver, and C. Lynde, “The relationship of obesity with the severity of psoriasis: A systematic review,” Journal of Cutaneous Medicine and Surgery, vol. 19, no. 5, pp. 450–456, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. L. E. Mokry, S. Ross, N. J. Timpson et al., “Obesity and multiple sclerosis: a mendelian randomization study,” PLoS Medicine, vol. 13, no. 6, Article ID e1002053, 2016. View at Publisher · View at Google Scholar
  35. R. Le Moli, V. Muscia, A. Tumminia et al., “Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 25, no. 5, pp. 452–457, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. A. Garrity and R. S. Bahn, “Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 147.e2–153.e2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Kumar, S. Nadeem, M. N. Stan, M. Coenen, and R. S. Bahn, “A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy,” Molecular Endocrinology, vol. 46, no. 3, pp. 155–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Pellegriti, A. Belfiore, D. Giuffrida, L. Lupo, and R. Vigneri, “Outcome of differentiated thyroid cancer in Graves' patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 8, pp. 2805–2809, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. F. H. Steffensen and N. A. Aunsholt, “Hyperthyroidism associated with metastatic thyroid carcinoma,” Clinical Endocrinology, vol. 41, no. 5, pp. 685–687, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Pellegriti, C. Mannarino, M. Russo et al., “Increased mortality in patients with differentiated thyroid cancer associated with graves' disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 3, pp. 1014–1021, 2013. View at Publisher · View at Google Scholar · View at Scopus